Finch Therapeutics Group, Inc. reported unaudited consolidated impairment of long-lived assets for the first quarter ended March 31, 2023. Impairment of long-lived assets was $13,141,000. The increase in net loss was primarily due to a charge of $32.9 million for the full impairment of the Company's in-process research and development (IPR&D) asset.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
2 USD | +4.17% | -0.50% | -44.60% |
1st Jan change | Capi. | |
---|---|---|
-44.60% | 3.08M | |
+33.80% | 50.85B | |
+0.33% | 42.82B | |
+49.62% | 42.03B | |
-4.96% | 29.55B | |
+10.94% | 26.11B | |
-22.01% | 19.13B | |
+8.80% | 13.05B | |
+27.10% | 12.16B | |
+24.47% | 12.08B |
- Stock Market
- Equities
- FNCH Stock
- News Finch Therapeutics Group, Inc.
- Finch Therapeutics Group, Inc. Reports Unaudited Consolidated Impairment of Long-Lived Assets for the First Quarter Ended March 31, 2023